Increased Sympathetic Drive, Elevated Heart Rate, and the Cardiovascular Continuum
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:8] [Pages No:105 - 112]
DOI: 10.5005/jp-journals-10043-0080 | Open Access | How to cite |
Abstract
Egan BM. Increased Sympathetic Drive, Elevated Heart Rate, and the Cardiovascular Continuum. Hypertens J 2017;3(3):105-112.How to cite this article
Hypertension in Pregnancy: Do We need a New Algorithm?
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:5] [Pages No:113 - 117]
DOI: 10.5005/jp-journals-10043-0081 | Open Access | How to cite |
Abstract
Nair T, Nair A. Hypertension in Pregnancy: Do We need a New Algorithm? Hypertens J 2017;3(3):113-117.How to cite this article
Biomarkers in Congestive Heart Failure: Clinical Importance
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:7] [Pages No:118 - 124]
DOI: 10.5005/jp-journals-10043-0082 | Open Access | How to cite |
Abstract
Banerjee AK. Biomarkers in Congestive Heart Failure: Clinical Importance. Hypertens J 2017;3(3):118-124.How to cite this article
Treatment-Resistant Hypertension: A Pragmatic Management Approach
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:6] [Pages No:125 - 130]
DOI: 10.5005/jp-journals-10043-0083 | Open Access | How to cite |
Abstract
Egan BM. Treatment-Resistant Hypertension: A Pragmatic Management Approach. Hypertens J 2017;3(3):125-130.How to cite this article
Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:8] [Pages No:131 - 138]
DOI: 10.5005/jp-journals-10043-0084 | Open Access | How to cite |
Abstract
Auchus RJ. Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism. Hypertens J 2017;3(3):131-138.How to cite this article
Assessment of End Organ Damage in Hypertension—Left Ventricular Hypertrophy
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:8] [Pages No:139 - 146]
DOI: 10.5005/jp-journals-10043-0085 | Open Access | How to cite |
Abstract
Deshpande MV, Deshpande NV. Assessment of End Organ Damage in Hypertension—Left Ventricular Hypertrophy. Hypertens J 2017;3(3):139-146.How to cite this article
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:7] [Pages No:147 - 153]
DOI: 10.5005/jp-journals-10043-0086 | Open Access | How to cite |
Abstract
Manoria PC, Mishra N. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Ready to Target Atherosclerotic Cardiovascular Disease beyond Statins. Hypertens J 2017;3(3):147-153.How to cite this article
Renal Effects of Sodium-glucose-linked Transporter 2 Inhibitors
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:7] [Pages No:154 - 160]
DOI: 10.5005/jp-journals-10043-0087 | Open Access | How to cite |
Abstract
Chakravarthi MR, Marri HK. Renal Effects of Sodium-glucose-linked Transporter 2 Inhibitors. Hypertens J 2017;3(3):154-160.How to cite this article
Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors
[Year:2017] [Month:July-September] [Volume:3] [Number:3] [Pages:5] [Pages No:161 - 165]
DOI: 10.5005/jp-journals-10043-0088 | Open Access | How to cite |
Abstract
“Current management of diabetes is characterized by opportunities, options, and obstacles.” —Dr Sanjay Kalra (2014) Iyengar SS. Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors. Hypertens J 2017;3(3):161-165.How to cite this article
© Jaypee Brothers Medical Publishers (P) LTD.
